$73.33-0.53 (-0.72%)
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. in the Healthcare sector is trading at $73.07 with a market capitalization of $10.0B. Wall Street consensus targets $88.17 (12 analysts), implying a +20.7% move over the next 12 months. The stock is currently near its 52-week high of $82.26, remaining 30.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of ang...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through
Arrowhead Pharmaceuticals presented new clinical data on plozasiran in patients with moderate to severe renal or hepatic impairment at a major scientific congress. The data focused on efficacy and safety outcomes in these higher risk groups. A separate case report highlighted long term triglyceride reduction with plozasiran use during pregnancy. For investors watching Arrowhead Pharmaceuticals (NasdaqGS:ARWR), these updates come with the stock at $74.95 and 1 year gains of 387.6%. The move...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best medical stocks to invest in according to billionaires. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) received a rating update from Bernstein on May 13. The firm lifted the price target on the stock to $46 from $35, maintaining a Market Perform rating on the shares and stating that biotech has had […]
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference. An